Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 232.78% is 644% above its 5-year average of -42.80%, near the high end of its 5-year range (-645.91%–232.78%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.11% above its 12-month average of 176.20%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 232.78%.
RETURN ON EQUITY (ROE)
232.78%
RETURN ON EQUITY (ROE) AVG TTM
176.20%
RETURN ON EQUITY (ROE) AVG 3Y
-64.11%
RETURN ON EQUITY (ROE) AVG 5Y
-42.80%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+32.11%
CURRENT VS 3Y AVG
+463.09%
CURRENT VS 5Y AVG
+643.84%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.76%
median of 593 covered companies
CURRENT VS SECTOR MEDIAN
+685.47%
vs the sector median at left
LENSAR Inc
Market Cap
$82.41M
Return on Equity (ROE)
232.78%
TTM Avg
176.20%
3Y Avg
-64.11%
5Y Avg
-42.80%
Market Cap
$83.04M
Return on Equity (ROE)
-85.65%
TTM Avg
-57.41%
3Y Avg
-45.73%
5Y Avg
-8.61%
Market Cap
$83.18M
Return on Equity (ROE)
-28.85%
TTM Avg
-24.95%
3Y Avg
-20.92%
5Y Avg
-19.20%
Market Cap
$81.57M
Return on Equity (ROE)
-130.67%
TTM Avg
-143.13%
3Y Avg
-106.90%
5Y Avg
-90.63%
Market Cap
$80.89M
Return on Equity (ROE)
-114.06%
TTM Avg
-50.52%
3Y Avg
-45.18%
5Y Avg
-45.18%
Market Cap
$80.04M
Return on Equity (ROE)
-122.76%
TTM Avg
-82.75%
3Y Avg
-63.80%
5Y Avg
-49.10%
Market Cap
$85.01M
Return on Equity (ROE)
-85.48%
TTM Avg
1586.35%
3Y Avg
184842.55%
5Y Avg
123293.37%
Market Cap
$78.76M
Return on Equity (ROE)
-1542.57%
TTM Avg
-254.55%
3Y Avg
-187.52%
5Y Avg
-143.69%
Market Cap
$85.01M
Return on Equity (ROE)
-50.80%
TTM Avg
-124.86%
3Y Avg
-88.30%
5Y Avg
-60.21%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LENSAR Inc (LNSR) | $82.41M | 232.78% | 176.20% | -64.11% | -42.80% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | -85.65% | -57.41% | -45.73% | -8.61% |
| MediciNova, Inc. (MNOV)vs › | $83.18M | -28.85% | -24.95% | -20.92% | -19.20% |
| Nutriband Inc. (NTRB)vs › | $81.57M | -130.67% | -143.13% | -106.90% | -90.63% |
| Citius Oncology, Inc. (CTOR)vs › | $80.89M | -114.06% | -50.52% | -45.18% | -45.18% |
| Pulmonx Corporation (LUNG)vs › | $80.04M | -122.76% | -82.75% | -63.80% | -49.10% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $85.01M | -85.48% | 1586.35% | 184842.55% | 123293.37% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.76M | -1542.57% | -254.55% | -187.52% | -143.69% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | -50.80% | -124.86% | -88.30% | -60.21% |
| Humacyte, Inc. (HUMA)vs › | $85.16M | -309.44% | -515.53% | -464.77% | -329.14% |
ROE
232.8%
ROA
49.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 232.78% |
| 2026-03-31 | 119.63% |
| 2024-12-31 | -645.91% |
| 2024-09-30 | -73.13% |
| 2024-06-30 | -33.55% |
| 2024-03-31 | -38.54% |
| 2023-12-31 | -43.03% |
| 2023-09-30 | -35.59% |
| 2023-06-30 | -59.67% |
| 2023-03-31 | -44.40% |
| 2022-12-31 | -47.43% |
| 2022-09-30 | -50.08% |
| 2022-06-30 | -52.31% |
| 2022-03-31 | -42.35% |
| 2021-12-31 | -35.72% |
| 2021-09-30 | -39.49% |
| 2021-06-30 | -34.29% |
| 2021-03-31 | -33.06% |
| 2020-12-31 | -29.42% |
| 2020-09-30 | -22.36% |
